###begin article-title 0
###xml 14 23 14 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
The impact of HLA-DRB1 genes on extra-articular disease manifestations in rheumatoid arthritis
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
###xml 43 52 43 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
###xml 56 65 56 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DQB1 </italic>
###xml 474 476 474 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 543 545 543 545 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 695 704 695 704 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
###xml 708 717 708 717 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DQB1 </italic>
###xml 820 828 820 828 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*04 </italic>
###xml 1015 1024 1015 1024 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
###xml 1028 1037 1028 1037 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DQB1 </italic>
###xml 1086 1096 1086 1096 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*0401 </italic>
###xml 1097 1099 1097 1099 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1112 1116 1112 1116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0401</italic>
###xml 1117 1122 1117 1122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0401 </italic>
###xml 1136 1138 1136 1138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1224 1236 1224 1236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*04 </italic>
###xml 1569 1582 1569 1582 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*0401</italic>
###xml 1663 1671 1663 1671 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*04 </italic>
###xml 78 86 <span type="species:ncbi:9606">patients</span>
###xml 211 219 <span type="species:ncbi:9606">patients</span>
###xml 260 268 <span type="species:ncbi:9606">Patients</span>
###xml 335 343 <span type="species:ncbi:9606">patients</span>
###xml 1053 1061 <span type="species:ncbi:9606">patients</span>
###xml 1472 1480 <span type="species:ncbi:9606">patients</span>
The objective of this study was to examine HLA-DRB1 and HLA-DQB1 genotypes in patients with severe extra-articular rheumatoid arthritis (ExRA) and to compare them with the genotypes of rheumatoid arthritis (RA) patients without extra-articular manifestations. Patients with severe ExRA were recruited from a large research database of patients with RA, from two cohorts of prevalent RA cases, and from a regional multicenter early RA cohort. Cases with ExRA manifestations (n = 159) were classified according to predefined criteria. Controls (n = 178) with RA but no ExRA were selected from the same sources. Cases and controls were matched for duration of RA and for clinical center. PCR based HLA-DRB1 and HLA-DQB1 genotyping was performed using the Biotest SSP kit, with additional sequencing in order to distinguish DRB1*04 subtypes. Associations between alleles and disease phenotypes were tested using multiple simulations of random distributions of alleles. There was no difference in global distribution of HLA-DRB1 and HLA-DQB1 alleles between patients with ExRA and controls. DRB1*0401 (P = 0.003) and 0401/0401 homozygosity (P = 0.002) were more frequent in Felty's syndrome than in controls. The presence of two HLA-DRB1*04 alleles encoding the shared epitope (SE) was associated with ExRA (overall odds ratio 1.79, 95% confidence interval 1.04-3.08) and with rheumatoid vasculitis (odds ratio 2.44, 95% confidence interval 1.22-4.89). In this large sample of patients with ExRA, Felty's syndrome was the only manifestation that was clearly associated with HLA-DRB1*0401. Other ExRA manifestations were not associated with individual alleles but with DRB1*04 SE double dose genotypes. This confirms that SE genes contribute to RA disease severity and ExRA. Other genetic and environmental factors may have a more specific impact on individual ExRA manifestations.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 341 342 341 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 343 344 343 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 451 452 451 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 534 535 534 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 98 106 <span type="species:ncbi:9606">patients</span>
###xml 374 382 <span type="species:ncbi:9606">patients</span>
Rheumatoid arthritis (RA) is a systemic inflammatory disease that, in a substantial proportion of patients, is associated with the development of extra-articular manifestations. These extra-articular RA (ExRA) manifestations can have a defining impact on disease outcome, including increased premature mortality compared with RA in general [1-4]. Severe ExRA occurs both in patients recently diagnosed with RA and in those with long-standing disease [2]. Suggested predictors of ExRA include clinical, serologic, and genetic factors [5].
###end p 4
###begin p 5
###xml 78 79 78 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 80 81 80 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 396 404 <span type="species:ncbi:9606">patients</span>
###xml 447 455 <span type="species:ncbi:9606">patients</span>
There is strong evidence of a role for genetic factors in the etiology of RA [6-8], and genetic polymorphisms are probably involved in the wide variation in disease expression. As for most diseases classified according to a list of criteria, rather than specific diagnostic tests, the disease phenotype in RA is heterogeneous. The presence of disease susceptibility alleles may define subsets of patients with different disease courses, including patients with mild, nonerosive disease and those with a true RA phenotype and progressive disease, with extensive joint damage and ExRA manifestations. On the other hand, genetic markers not related to disease susceptibility may influence disease progression and risk for developing ExRA.
###end p 5
###begin p 6
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA </italic>
###xml 162 170 162 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1</italic>
###xml 187 195 187 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*04 </italic>
###xml 199 207 199 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*01 </italic>
###xml 216 217 216 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 354 356 354 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 357 359 357 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 376 388 376 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*04 </italic>
###xml 455 457 455 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 458 460 458 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 520 522 520 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 556 568 556 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*04 </italic>
###xml 688 690 688 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 709 721 709 721 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*04 </italic>
###xml 771 779 771 779 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*04 </italic>
###xml 837 839 837 839 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 840 842 840 842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 870 878 870 878 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*04 </italic>
###xml 962 966 962 966 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0401</italic>
###xml 967 972 967 972 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0401 </italic>
###xml 982 984 982 984 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 985 987 985 987 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1019 1023 1019 1023 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0401</italic>
###xml 1024 1029 1024 1029 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0404 </italic>
###xml 1084 1086 1084 1086 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1164 1178 1164 1178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*0401 </italic>
###xml 1253 1263 1253 1263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*0401 </italic>
###xml 1275 1285 1275 1285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*0405 </italic>
###xml 1320 1329 1320 1329 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
###xml 1339 1341 1339 1341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1450 1452 1450 1452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 5 10 <span type="species:ncbi:9606">human</span>
###xml 425 433 <span type="species:ncbi:9606">patients</span>
###xml 664 672 <span type="species:ncbi:9606">patients</span>
###xml 1064 1072 <span type="species:ncbi:9606">patients</span>
HLA (human leukocyte antigen) alleles have been implicated in a number of chronic inflammatory diseases. RA has been associated with the 'shared epitope' (SE) of HLA-DRB1, which includes DRB1*04 and DRB1*01 alleles [9]. Recent genome-wide scanning studies using microsatellite loci have confirmed that there is strong linkage between this region and RA [10,11]. RA-associated HLA-DRB1*04 alleles have been reported mainly in patients with severe disease [12-16]. A meta-analysis of studies of disease progression in RA [17] revealed an association between HLA-DRB1*04 and erosive disease, and in a recently reported survey of an extensively investigated cohort of patients with early RA [18] homozygosity for HLA-DRB1*04 was a major predictor of development of erosions. DRB1*04 alleles have also been specifically associated with ExRA [19-21], and a specific impact of DRB1*04 homozygosity has been suggested. Some authors have reported an association with the 0401/0401 genotype [21,22] whereas others have found the 0401/0404 genotype to be more frequent among patients with ExRA [23]. These discrepancies may reflect variability in the relative frequencies of HLA-DRB1*0401 in different populations. For example, in East Asian populations, in which DRB1*0401 is rare and DRB1*0405 is the most frequent RA associated HLA-DRB1 genotype [24], the latter allele has also been reported to be associated with an increased risk for ExRA manifestations [25].
###end p 6
###begin p 7
###xml 290 299 290 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DQB1 </italic>
###xml 479 481 479 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 110 117 <span type="species:ncbi:9606">patient</span>
All previous studies of major histocompatibility class (MHC) class II genes and ExRA have been based on small patient samples, limiting the generalizability of the results. Most studies were not sufficiently powered to examine the effect of linkage disequilibrium within the MHC, including HLA-DQB1 alleles. Previous investigations did not use consistent and well characterized definitions of ExRA, which is a matter of vital importance to the study of disease phenotypes in RA [26].
###end p 7
###begin p 8
###xml 66 75 66 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
###xml 79 88 79 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DQB1 </italic>
###xml 388 396 388 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*04 </italic>
###xml 457 462 457 462 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1 </italic>
###xml 166 174 <span type="species:ncbi:9606">patients</span>
###xml 256 264 <span type="species:ncbi:9606">patients</span>
###xml 312 320 <span type="species:ncbi:9606">patients</span>
The purpose of this study was to investigate associations between HLA-DRB1 and HLA-DQB1 alleles and severe ExRA manifestations in a multicenter case-control study of patients with well characterized disease. To our knowledge, this is the largest sample of patients with severe ExRA ever reported. We report that patients with ExRA manifestations are more likely to carry a double dose of DRB1*04 SE alleles, and we demonstrate that the impact of individual DRB1 alleles is limited.
###end p 8
###begin title 9
Materials and methods
###end title 9
###begin title 10
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 10
###begin p 11
###xml 60 61 60 61 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 62 63 62 63 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 874 875 874 875 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1031 1032 1031 1032 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 1033 1034 1033 1034 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 1035 1036 1035 1036 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1315 1317 1315 1317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 129 133 <span type="species:ncbi:162683">Mayo</span>
###xml 196 204 <span type="species:ncbi:9606">patients</span>
###xml 899 907 <span type="species:ncbi:9606">patients</span>
###xml 1089 1096 <span type="species:ncbi:9606">patient</span>
###xml 1135 1142 <span type="species:ncbi:9606">patient</span>
Patients with severe ExRA according to predefined criteria [2,3] were recruited from the rheumatology laboratory database of the Mayo Clinic (Rochester, MN, USA), from two clinic-based cohorts of patients with ExRA from Malmo University Hospital and Lund University Hospital (Sweden), and from a Swedish multicenter early RA cohort (the Better AntiRheumatic PharmacOTherapy [BARFOT] cohort). ExRA manifestations studied included pericarditis, pleuritis, Felty's syndrome, scleritis, episcleritis, glomerulonephritis, vasculitis-related neuropathy, major cutaneous vasculitis, and vasculitis involving other organs. Felty's syndrome was defined as RA-associated neutropenia and splenomegaly, with other potential causes excluded or unlikely. In addition, the criteria for severe ExRA were modified to include RA-associated interstitial lung disease, as previously described [5]. Controls, defined as patients with RA without current or previous signs of extra-articular disease manifestations, in accordance with the same criteria [2,3,5], were selected from the corresponding centers. One patient with RA (control) was matched to each patient with ExRA (case) according to duration of RA and clinical center. All cases and controls fulfilled 1987 American College of Rheumatology criteria for classification of RA [27].
###end p 11
###begin p 12
###xml 244 246 244 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 526 530 524 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA </italic>
###xml 13 21 <span type="species:ncbi:9606">patients</span>
###xml 103 107 <span type="species:ncbi:162683">Mayo</span>
###xml 272 280 <span type="species:ncbi:9606">patients</span>
Eighty-eight patients fulfilling the predefined criteria for ExRA (see above) were identified from the Mayo Clinic rheumatology laboratory database, and their medical case records were subjected to a structured review, as previously described [22]. A random sample of 184 patients with RA but without ExRA were identified from this database after careful medical record review. Controls from this sample were matched with cases for duration of RA +/- 5 years. DNA samples were available from 86 ExRA cases and 85 controls for HLA typing.
###end p 12
###begin p 13
###xml 536 538 534 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 980 982 978 980 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1031 1038 1029 1036 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DR </italic>
###xml 1042 1049 1040 1047 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DQ </italic>
###xml 1113 1115 1111 1113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 18 26 <span type="species:ncbi:9606">patients</span>
###xml 223 231 <span type="species:ncbi:9606">patients</span>
###xml 331 339 <span type="species:ncbi:9606">Patients</span>
###xml 396 404 <span type="species:ncbi:9606">patients</span>
###xml 505 513 <span type="species:ncbi:9606">patients</span>
###xml 628 636 <span type="species:ncbi:9606">patients</span>
###xml 670 678 <span type="species:ncbi:9606">patients</span>
###xml 756 764 <span type="species:ncbi:9606">patients</span>
###xml 790 798 <span type="species:ncbi:9606">patients</span>
###xml 1078 1086 <span type="species:ncbi:9606">patients</span>
Another cohort of patients was recruited from a prospective study of extra-articular disease manifestations and vascular comorbidities in RA from the rheumatology outpatient clinic of Malmo University Hospital. Consecutive patients with recently diagnosed severe extra-articular disease manifestations were invited to participate. Patients with non-extra-articular RA, matched to extra-articular patients for age, sex and disease duration (+/- 1 year), were selected from a community-based register of RA patients in the city of Malmo [28] or from a community-based early RA inception cohort from the same area. Samples from 28 patients with ExRA (cases) and 28 matched patients with RA but without ExRA (controls) were available for analysis. Thirty-five patients with ExRA (cases) and 42 patients with RA but without extra-articular disease (controls), matched for disease duration, from a case-control study of predictors of ExRA at the University Hospitals in Malmo and Lund [22] were also included in the analysis. Results of HLA-DR and HLA-DQ genotyping for some of these patients were reported previously [22].
###end p 13
###begin p 14
###xml 63 65 63 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 530 532 530 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 765 767 765 767 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 835 836 835 836 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 837 838 837 838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 13 21 <span type="species:ncbi:9606">patients</span>
###xml 83 91 <span type="species:ncbi:9606">patients</span>
###xml 229 237 <span type="species:ncbi:9606">patients</span>
###xml 436 444 <span type="species:ncbi:9606">patients</span>
###xml 583 591 <span type="species:ncbi:9606">patients</span>
###xml 714 722 <span type="species:ncbi:9606">patients</span>
###xml 854 862 <span type="species:ncbi:9606">patients</span>
In addition, patients were recruited from the BARFOT registry [29], which includes patients participating in a structured program for follow up of newly diagnosed RA in southern Sweden. This registry includes virtually all adult patients with new onset of inflammatory polyarthritis within the catchment area of the six participating rheumatology centers of the BARFOT program (total population is approximately 1.5 million), including patients fulfilling the 1987 American College of Rheumatology classification criteria for RA [27]. From 1992 to 2001, a total of 1,589 consecutive patients were recruited to the registry. Referring rheumatologists are encouraged to report ExRA manifestations occurring in these patients to the register. All reported ExRA cases (n = 35) were reviewed and classified according to the study criteria [2,3]. Of these, 26 patients fulfilled the criteria for ExRA. Controls without ExRA were matched to the cases by sex, age at inclusion, disease duration and, when possible, geographic region. All potential controls were reviewed in order to ensure that they did not have a history of ExRA. Samples for genotyping were available from ten ExRA cases and 24 non-ExRA controls in this subset.
###end p 14
###begin p 15
###xml 185 193 <span type="species:ncbi:9606">patients</span>
###xml 244 252 <span type="species:ncbi:9606">patients</span>
###xml 297 301 <span type="species:ncbi:162683">Mayo</span>
Data on serologic tests for rheumatoid factor (RF) and antinuclear antibodies (ANAs), and information on smoking status are prospectively collected as part of a structured follow up of patients in the BARFOT study. Data on these parameters for patients from the other centers (Malmo, Lund and the Mayo Clinic) were obtained by thorough review of all available clinical records.
###end p 15
###begin p 16
###xml 4 12 <span type="species:ncbi:9606">patients</span>
###xml 184 188 <span type="species:ncbi:162683">Mayo</span>
All patients gave informed consent to participate in the study. The study was approved by the Research Ethics Committee at Lund University and by the Institutional Review Board at the Mayo Clinic.
###end p 16
###begin title 17
Genotyping
###end title 17
###begin p 18
###xml 8 22 8 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1/DQB1 </italic>
###xml 532 541 532 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
###xml 545 554 545 554 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DQB1 </italic>
###xml 698 710 698 710 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*04 </italic>
###xml 765 777 765 777 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*04 </italic>
###xml 840 852 840 852 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*04 </italic>
###xml 891 902 891 902 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*04</italic>
###xml 938 947 938 947 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
###xml 1203 1212 1203 1212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
###xml 1258 1270 1258 1270 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*04 </italic>
###xml 1386 1395 1386 1395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*0401</italic>
###xml 1409 1414 1409 1414 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*0409</italic>
###xml 1416 1421 1416 1421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*0413</italic>
###xml 1423 1429 1423 1429 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*0416 </italic>
###xml 1433 1439 1433 1439 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*0421 </italic>
###xml 1458 1463 1458 1463 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*0401</italic>
###xml 1473 1478 1473 1478 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*0408</italic>
###xml 1480 1486 1480 1486 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*0410 </italic>
###xml 1490 1496 1490 1496 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*0419 </italic>
###xml 1515 1520 1515 1520 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*0404</italic>
###xml 1526 1536 1526 1536 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*0405 </italic>
###xml 1590 1598 1590 1598 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*04 </italic>
###xml 1625 1633 1625 1633 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*04 </italic>
###xml 32 40 <span type="species:ncbi:9606">patients</span>
###xml 60 64 <span type="species:ncbi:162683">Mayo</span>
###xml 226 234 <span type="species:ncbi:9606">patients</span>
###xml 1079 1083 <span type="species:ncbi:162683">Mayo</span>
DNA for HLA-DRB1/DQB1 typing of patients recruited from the Mayo Clinic was isolated from peripheral blood mononuclear cells using the DNA Isolation Kit for Mammalian Blood (Roche Applied Sciences, Indianapolis, IN, USA). For patients from the Swedish RA cohorts, DNA was extracted from whole blood using the QIAamp minikit (Qiagen, Hilden, Germany) at the DNA/RNA Genotyping Laboratory, SWEGENE Resource Center for Profiling Polygenic Diseases (Lund University and Malmo University Hospital, Sweden). The purified DNA was used for HLA-DRB1 and HLA-DQB1 determination with the PCR-based Micro-SSP DRB and DQB generic typing trays (Biotest AG, Dreiech, Germany). Because the DRB kit does not detect HLA-DRB1*04 allelic variations, all samples that were positive for HLA-DRB1*04 were re-amplified by PCR using a primer set that amplified all HLA-DRB1*04 alleles: 5'-GTTTCTTGGAGCAGGTTAAACA-3' (HLA-DRB1*04) and 5'-GCCGCTGCACTGTGAAGCTCTC-3' (HLA-DRB1 generic). Samples were then purified using the High Pure PCR Product Purification Kit (Roche Applied Sciences) and sequenced in the Mayo Clinic molecular biology core facility on a PRISM 37 DNA Sequencer (Applied Biosystems, Foster City, CA, USA) with the HLA-DRB1 primer as the initiating primer. The specific HLA-DRB1*04 allele was then assigned on the basis of the sequencing results. For the statistical analysis, the SE encoding rare DRB1*0401-like alleles *0409, *0413, *0416 and *0421 were classified as *0401; alleles *0408, *0410 and *0419 were classified as *0404. The DRB1*0405 alleles were analyzed as a separate entity. All other DRB1*04 alleles were classified as DRB1*04 non-SE alleles.
###end p 18
###begin title 19
Statistical analysis
###end title 19
###begin p 20
###xml 319 321 317 319 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 198 206 <span type="species:ncbi:9606">patients</span>
The age at RA diagnosis and the duration of RA at inclusion in ExRA cases and non-ExRA controls with RA were compared using the t test. The sex distribution, the number of smokers and the number of patients with a positive RF test or ANA test at any time were compared between the cases and controls using Pearson's chi2 statistic.
###end p 20
###begin p 21
###xml 276 278 274 276 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 381 383 379 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 442 444 440 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 926 935 924 933 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
###xml 939 948 937 946 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DQB1 </italic>
###xml 1053 1055 1051 1053 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1249 1251 1247 1249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1368 1377 1366 1375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
###xml 1381 1384 1379 1382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DQ </italic>
###xml 1418 1430 1416 1428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1-DQ </italic>
###xml 154 160 <span type="species:ncbi:9606">person</span>
To compare the distribution of alleles between cases and controls, we used Armitage's trend in proportions, which does not treat the two alleles within a person as independent (i.e. it does not assume Hardy-Weinberg equilibrium). This approach reduces to the usual Pearson chi2 statistic for comparing allele frequencies when genotype proportions match Hardy-Weinberg proportions [30], and is the preferred way to compare allele frequencies [31]. However, the usual Armitage test for trend is for only two alleles. A multivariate extension for more than two alleles, which compares allele counts between cases and controls, is based on the score statistic for logistic regression. For this score statistic, each subject receives a vector of scores, where each element of the vector counts alleles of each type. From this score statistic, we computed a global test of association between case/control status and all alleles of HLA-DRB1 and HLA-DQB1 separately. Because the distribution of this statistic is not known, we performed simulations to compute P values. The case/control status was randomly permuted, and the simulated statistic computed and compared with the observed statistic. This simulation process was repeated 1,000 times to compute P values, both for the maximum statistic and allele-specific Armitage trend tests. The distribution of combinations of HLA-DRB1 and DQ alleles (i.e. the distribution of HLA-DRB1-DQ haplotypes) was similarly compared in cases and controls.
###end p 21
###begin p 22
###xml 56 68 56 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*04 </italic>
To evaluate the association of single or double dose of HLA-DRB1*04 SE subtypes with case/control status, or with a particular manifestation of ExRA, we used logistic regression to calculate odds ratios (ORs) and 95% confidence interval (CI).
###end p 22
###begin title 23
Results
###end title 23
###begin p 24
###xml 75 76 75 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 77 79 77 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 312 314 312 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 348 350 348 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 375 377 375 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 401 403 401 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 662 663 662 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 751 753 751 753 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 901 903 901 903 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 922 924 922 924 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 15 23 <span type="species:ncbi:9606">patients</span>
###xml 110 118 <span type="species:ncbi:9606">patients</span>
###xml 723 731 <span type="species:ncbi:9606">patients</span>
A total of 159 patients with severe ExRA according to predefined criteria [5,23] were identified. Forty-three patients had vasculitis, defined as biopsy proven vasculitis or major cutaneous vasculitis diagnosed by a dermatologist. Additional subgroups analyzed were neuropathy (mononeuropathy or polyneuropathy; n = 40), interstitial lung disease (n = 25), Felty's syndrome (n = 21) and pericarditis (n = 27). These were compared with 178 controls with non-extra-articular RA. Disease duration and age at RA onset was similar in cases and controls (mean 11.3 years versus 12.5 years for duration, and mean 50.1 years versus 50.4 years for age at RA onset; Table 1). There was a trend toward a relative predominance of male patients in the ExRA group (P = 0.06). However, this comparison is skewed because of the matching of cases and controls for sex in two of the subsamples. A positive test for RF (P < 0.0001) or ANAs (P < 0.0001) at any time were both significantly associated with ExRA.
###end p 24
###begin p 25
###xml 112 120 <span type="species:ncbi:9606">patients</span>
Some of the individual severe ExRA manifestations occurred together more frequently than expected. Among the 21 patients with Felty's syndrome, three (14%) had evidence of vasculitis. In the subset with vasculitis, 15 out of 43 (35%) had neuropathy and seven (16%) had interstitial lung disease.
###end p 25
###begin title 26
###xml 19 22 19 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA</italic>
###xml 23 28 23 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1 </italic>
Overall effects of HLA-DRB1 alleles
###end title 26
###begin p 27
###xml 20 29 20 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
###xml 110 112 110 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 126 127 126 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 148 157 148 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
###xml 183 196 183 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*0401</italic>
###xml 302 304 302 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 313 327 313 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*0401 </italic>
###xml 403 405 403 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 507 508 507 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 527 539 527 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*12 </italic>
###xml 614 616 614 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 629 639 629 639 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*0405 </italic>
###xml 677 679 677 679 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 691 701 691 701 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*0404 </italic>
###xml 739 741 739 741 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 841 853 841 853 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*04 </italic>
###xml 878 887 878 887 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*0401</italic>
###xml 889 894 889 894 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*0404</italic>
###xml 899 904 899 904 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*0405</italic>
###xml 1058 1066 1058 1066 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*04 </italic>
###xml 1146 1147 1146 1147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 1208 1216 1208 1216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*04 </italic>
###xml 1407 1408 1407 1408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 245 253 <span type="species:ncbi:9606">patients</span>
###xml 784 792 <span type="species:ncbi:9606">patients</span>
###xml 941 949 <span type="species:ncbi:9606">patients</span>
###xml 990 998 <span type="species:ncbi:9606">patients</span>
###xml 1150 1158 <span type="species:ncbi:9606">Patients</span>
###xml 1232 1240 <span type="species:ncbi:9606">patients</span>
The distribution of HLA-DRB1 was not significantly different between ExRA cases and non-ExRA controls (global P = 0.19; Table 2). The most frequent HLA-DRB1 allele in both groups was HLA-DRB1*0401, and this allele tended to be more common among patients with ExRA (allele frequency 0.326 versus 0.263; P = 0.09). HLA-DRB1*0401 was significantly associated with Felty's syndrome (allele frequency 0.475; P = 0.003) but not with other individual manifestations when compared with non-extra-articular RA (Fig. 1). The rare allele HLA-DRB1*12 was more common in the ExRA subgroup (allele frequency 0.023 versus 0.003; P = 0.02). The DRB1*0405 (allele frequency 0.019 versus 0.003; P = 0.01) and DRB1*0404 (allele frequency 0.119 versus 0.085; P = 0.14) alleles were also more frequent in patients with ExRA than in non-ExRA controls. One of the HLA-DRB1*04 alleles encoding the SE (DRB1*0401, *0404, or *0405) was present in 105 out of 151 ExRA patients as compared with 96 out of 178 non-ExRA patients (OR 1.77, 95% CI 1.13-2.77). The impact of the presence of DRB1*04 SE alleles on risk for ExRA was variable for the different manifestations (Fig. 2). Patients with RA and vasculitis were more likely to carry DRB1*04 SE alleles than patients with RA and no vasculitis (OR 2.07, 95% CI 1.00-4.25). Similar trends were found for Felty's syndrome and neuropathy, but the associations were not significant (Fig. 2).
###end p 27
###begin title 28
Effects of homozygosity for the shared epitope
###end title 28
###begin p 29
###xml 24 43 24 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*0401/0401 </italic>
###xml 136 138 136 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 205 207 205 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 366 378 366 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*04 </italic>
###xml 727 739 727 739 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*04 </italic>
###xml 757 758 757 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 78 86 <span type="species:ncbi:9606">patients</span>
###xml 151 159 <span type="species:ncbi:9606">patients</span>
###xml 568 576 <span type="species:ncbi:9606">patients</span>
The homozygous genotype HLA-DRB1*0401/0401 was significantly more frequent in patients with Felty's syndrome (genotype frequency 0.286; P = 0.002) and patients with pericarditis (genotype frequency 0.185; P = 0.043) than in non-ExRA controls (frequency 0.068). Other ExRA manifestations were not associated with any specific homozygous genotype. The presence of two HLA-DRB1*04 SE alleles was significantly associated with ExRA overall (OR 1.79, 95% CI 1.04-3.08), Felty's syndrome (OR 2.63, 95% CI 1.04-6.63), and vasculitis (OR 2.44, 95% CI 1.22-4.89) compared with patients with RA who lacked these manifestations. By contrast, pericarditis, neuropathy, and interstitial lung disease were not associated with double dose of HLA-DRB1*04 SE alleles (Table 3).
###end p 29
###begin title 30
###xml 11 19 11 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DQB </italic>
Effects of HLA-DQB alleles
###end title 30
###begin p 31
###xml 20 28 20 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DQB </italic>
###xml 110 112 110 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 126 127 126 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 157 165 157 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DQ4 </italic>
###xml 249 251 249 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 335 339 335 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DQB </italic>
###xml 513 521 513 521 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DQB </italic>
###xml 606 608 606 608 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 617 629 617 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DQ8/DQ8 </italic>
###xml 762 764 762 764 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 355 363 <span type="species:ncbi:9606">patients</span>
###xml 569 577 <span type="species:ncbi:9606">patients</span>
###xml 661 669 <span type="species:ncbi:9606">patients</span>
###xml 705 713 <span type="species:ncbi:9606">patients</span>
The distribution of HLA-DQB alleles was not significantly different between ExRA cases and non-ExRA controls (P = 0.11; Table 4). The relatively rare allele HLA-DQ4 tended to occur more frequently in ExRA cases (allele frequency 0.046 versus 0.014; P = 0.037). Other than that, there was no significant difference in the occurrence of DQB alleles between patients with ExRA overall or individual ExRA manifestations and non-ExRA controls. There was no significant global difference in the frequency of homozygous HLA-DQB genotypes between cases and controls except for patients with ExRA and pericarditis (P = 0.04). HLA-DQ8/DQ8 homozygosity was more common in patients with pericarditis than in non-ExRA patients with RA (genotype frequency 0.120 versus 0.029; P = 0.021).
###end p 31
###begin title 32
Analyses of linkage disequilibrium
###end title 32
###begin p 33
###xml 67 79 67 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*04 </italic>
###xml 128 136 128 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*04 </italic>
###xml 195 208 195 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1-DQB </italic>
###xml 294 303 294 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*0401</italic>
###xml 334 342 334 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DQ8/DQ8 </italic>
###xml 364 373 364 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1-DQB </italic>
Haplotype analysis indicated that the association between ExRA and HLA-DRB1*04 SE homozygosity was due to the importance of the DRB1*04 genotype, rather than being secondary to associations with HLA-DRB1-DQB haplotypes (data not shown). Similarly, the associations between Felty's syndrome and DRB1*0401, and between pericarditis and DQ8/DQ8 were not explained by DRB1-DQB haplotype associations.
###end p 33
###begin title 34
Discussion
###end title 34
###begin p 35
###xml 99 112 99 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*0401</italic>
###xml 180 189 180 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
###xml 192 200 192 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DQB </italic>
###xml 355 367 355 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*04 </italic>
###xml 420 428 420 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*04 </italic>
###xml 24 32 <span type="species:ncbi:9606">patients</span>
###xml 303 311 <span type="species:ncbi:9606">Patients</span>
In this large sample of patients with severe ExRA, we found Felty's syndrome to be associated with HLA-DRB1*0401. There was no significant difference in the global distribution of HLA-DRB1 or HLA-DQB alleles compared with non-extra-articular RA controls for any other manifestation or for ExRA overall. Patients with severe ExRA were more likely to carry HLA-DRB1*04 SE alleles, and genotypes featuring a double dose of DRB1*04 SE alleles were associated with rheumatoid vasculitis, Felty's syndrome, and all ExRA combined.
###end p 35
###begin p 36
###xml 46 54 46 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DR4 </italic>
###xml 77 79 77 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 162 177 162 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*0401/0401 </italic>
###xml 205 207 205 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 208 210 208 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 242 251 242 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
###xml 347 349 347 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 409 418 409 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0401/0401</italic>
###xml 420 429 420 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0401/0404</italic>
###xml 435 444 435 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0401/0101</italic>
###xml 503 511 503 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*04 </italic>
###xml 622 624 622 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 719 721 719 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 769 777 769 777 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*04 </italic>
###xml 273 281 <span type="species:ncbi:9606">patients</span>
A number of studies have indicated a role for HLA-DR4 related genes in ExRA [26]. In Caucasians of Northern European origin, severe ExRA has been associated with DRB1*0401/0401 homozygosity in particular [21,22]. In a recent meta-analysis of HLA-DRB1 genotyping studies of patients with RA-associated vasculitis conducted by Gorman and coworkers [32], vasculitis was found to be associated with the genotypes 0401/0401, 0401/0404, and 0401/0101. In other meta-analyses by the same group, double dose of DRB1*04 SE alleles was associated with radiographic signs of progressive joint damage in northern European Caucasians [17], but there was no significant association between SE and the presence of rheumatoid nodules [33]. Taken together, these findings indicate that DRB1*04 SE double gene dose is associated with disease severity in RA, and that such genotypes may contribute specifically to risk for severe ExRA manifestations.
###end p 36
###begin p 37
###xml 140 150 140 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*0401 </italic>
###xml 171 173 171 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 174 176 174 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 261 269 261 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*04 </italic>
###xml 391 400 391 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
###xml 283 291 <span type="species:ncbi:9606">patients</span>
On the other hand, there was considerable heterogeneity across individual ExRA manifestations. The association between Felty's syndrome and DRB1*0401 is well established [34,35]. In contrast, we did not observe any significant association with single or double DRB1*04 gene dose for patients with pericarditis, neuropathy, or interstitial lung disease. This indicates that the importance of HLA-DRB1 alleles may be variable for different manifestations, although our failure to detect an effect could be due to sample size or selection.
###end p 37
###begin p 38
###xml 75 77 75 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 213 215 213 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 275 287 275 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*04 </italic>
###xml 357 359 357 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 57 65 <span type="species:ncbi:9606">patients</span>
###xml 117 125 <span type="species:ncbi:9606">patients</span>
Severe ExRA manifestations tend to cluster in individual patients with RA [36]. The high prevalence of vasculitis in patients with Felty's syndrome observed in the present study is consistent with the literature [37], and may in part be due to shared genetic factors such as HLA-DRB1*04 alleles. In a survey of the community-based Olmsted county RA cohort [36] we found clustering of a number of different ExRA features, including a frequent co-occurrence of vasculitis with neuropathy and rheumatoid lung disease. We made similar observations in the present study. Such clustering may be explained by both genetic and environmental factors.
###end p 38
###begin p 39
###xml 24 33 24 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
###xml 172 174 172 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 609 611 609 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 612 614 612 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 748 750 748 750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 820 822 820 822 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 850 852 850 852 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 880 881 880 881 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 885 887 885 887 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 894 896 894 896 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 897 899 897 899 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 919 921 919 921 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 976 978 976 978 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 999 1008 999 1008 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
###xml 642 650 <span type="species:ncbi:9606">patients</span>
###xml 777 785 <span type="species:ncbi:9606">patients</span>
The association between HLA-DRB1 genotypes and RA disease severity, including ExRA, has been interpreted as reflecting the importance of T cells in the pathogenesis of RA [26]. HLA-DR and other MHC molecules are involved in presentation of antigens to T cells, and in positive and negative selection of T cells in the thymus. Because there appears to be a stoichiometric relationship between MHC molecules on the cell surface and positive selection mechanisms in thymic maturation of T cells, it has been suggested that the explanation for the gene dose effect seen in ExRA is its effect on T-cell diversity [21,38]. The T-cell repertoire in patients with RA is markedly contracted, with less diversity and emergence of dominant T-cell clonotypes [39]. T-cell abnormalities in patients with ExRA include expansion of CD8+ large granular lymphocytes [40] and of immunosenescent CD4+CD28- cells [41,42], and extensive CD4+ infiltrates in RA-associated interstitial pneumonitis [43]. The importance of HLA-DRB1 genes and other genes with a role in T-cell selection and T-cell function for these phenomena require further study.
###end p 39
###begin p 40
###xml 119 121 119 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 122 124 122 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 46 54 <span type="species:ncbi:9606">patients</span>
In accordance with previous studies, we found patients with ExRA to be more likely to be RF positive and ANA positive [22,44]. This suggests a role for both B cells and T cells, possibly including dysregulated B cell-T cell interaction, in ExRA.
###end p 40
###begin p 41
###xml 226 231 226 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1 </italic>
###xml 235 240 235 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DQB1 </italic>
###xml 254 262 254 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*12 </italic>
###xml 266 269 266 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DQ4</italic>
###xml 328 337 328 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
###xml 394 402 394 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*04 </italic>
###xml 503 510 <span type="species:ncbi:9606">patient</span>
New genetic associations that were not postulated and have not been reproduced should be interpreted with caution. Given the nonsignificant results of the global distribution tests, the associations between ExRA and some rare DRB1 and DQB1 alleles (i.e. DRB1*12 and DQ4) are probably due to chance. The negative global test for HLA-DRB1 alleles in ExRA overall also suggests that the impact of DRB1*04 SE on the risk for severe ExRA manifestations is not strong, although it is reproducible in separate patient samples.
###end p 41
###begin p 42
###xml 41 50 41 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DQB1 </italic>
###xml 92 106 92 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1-DQB1 </italic>
###xml 144 153 144 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
The lack of association between ExRA and HLA-DQB1 alleles, and the lack of association with HLA-DRB1-DQB1 haplotypes favors a specific role for HLA-DRB1 genes in ExRA, rather than secondary associations due to linked genes. Nevertheless, we cannot exclude the possibility that linkage disequilibrium with other genes in MHC explain our results.
###end p 42
###begin p 43
###xml 4 12 <span type="species:ncbi:9606">patients</span>
###xml 191 199 <span type="species:ncbi:9606">patients</span>
###xml 244 248 <span type="species:ncbi:162683">Mayo</span>
###xml 282 290 <span type="species:ncbi:9606">patients</span>
###xml 360 368 <span type="species:ncbi:9606">patients</span>
###xml 462 470 <span type="species:ncbi:9606">patients</span>
The patients included in this study were recruited from four different centers, and the background RA population from which they were sampled is not fully characterized, at least not for the patients seen at Lund University Hospital and at the Mayo Clinic. On the other hand, these patients were recruited during a period when there was particular interest in patients with severe ExRA at each of the centers, suggesting that they should reflect the majority of patients with ExRA seen and be representative of the ExRA population as a whole.
###end p 43
###begin p 44
###xml 79 86 <span type="species:ncbi:9606">patient</span>
###xml 144 152 <span type="species:ncbi:9606">patients</span>
###xml 169 173 <span type="species:ncbi:162683">Mayo</span>
###xml 241 249 <span type="species:ncbi:9606">patients</span>
###xml 316 324 <span type="species:ncbi:9606">patients</span>
In multicenter studies of genetic markers, ethnic heterogeneity of the studied patient samples must be considered. However, the majority of the patients included at the Mayo Clinic were Caucasians of northern European origin, similar to the patients from southern Sweden. Thus, our result could be generalized to RA patients with this ethnic background but not to other populations.
###end p 44
###begin title 45
Conclusion
###end title 45
###begin p 46
###xml 93 107 93 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*0401 </italic>
###xml 226 235 226 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
###xml 256 268 256 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*04 </italic>
###xml 32 40 <span type="species:ncbi:9606">patients</span>
In a study of a large sample of patients with ExRA, we have confirmed an association between HLA-DRB1*0401 and Felty's syndrome, but we found no association between ExRA overall or other individual manifestations and specific HLA-DRB1 alleles. Double dose HLA-DRB1*04 SE genotypes are associated with a modestly increased risk for vasculitis and other ExRA manifestations. Other genetic and environmental factors are likely to be more important for the systemic features of RA.
###end p 46
###begin title 47
Abbreviations
###end title 47
###begin p 48
###xml 105 110 <span type="species:ncbi:9606">human</span>
ANA = antinuclear antibody; CI = confidence interval; ExRA = extra-articular rheumatoid arthritis; HLA = human leukocyte antigen; MHC = major histocompatibility complex; OR = odds ratio; PCR = polymerase chain reaction; RF = rheumatoid factor; SE = shared epitope.
###end p 48
###begin title 49
Competing interests
###end title 49
###begin p 50
The authors declare that they have no competing interests.
###end p 50
###begin title 51
Authors' contributions
###end title 51
###begin p 52
###xml 82 90 <span type="species:ncbi:9606">patients</span>
###xml 285 293 <span type="species:ncbi:9606">patients</span>
###xml 349 357 <span type="species:ncbi:9606">patients</span>
###xml 471 479 <span type="species:ncbi:9606">patients</span>
###xml 580 588 <span type="species:ncbi:9606">patients</span>
###xml 664 672 <span type="species:ncbi:9606">patients</span>
###xml 818 826 <span type="species:ncbi:9606">patients</span>
CT conceived the study, was responsible for the recruitment and classification of patients, and drafted the manuscript. DS performed the statistical analysis and helped to draft the manuscript. CW participated in the design and coordination of the study, and recruited a subset of the patients. LJ participated in the recruitment of a subset of the patients and the interpretation of the statistical data, and helped to draft the manuscript. JG recruited a subset of the patients and participated in the design and coordination of the study. GS participated in the recruitment of patients and the molecular genetics analysis. IP participated in the recruitment of patients, the extraction of clinical data, and the interpretation of the statistical analysis. BMNW participated in the recruitment and classification of patients and the extraction of clinical data. LT performed part of the molecular genetics analysis and helped to draft the manuscript. SD performed part of the molecular genetics analysis and participated in the coordination of the study. EM conceived the study together with CT, performed part of the molecular genetics analysis, participated in the design and coordination of the study, and in the interpretation of the statistical data, and helped to draft the manuscript. All authors read and approved the final manuscript.
###end p 52
###begin title 53
Acknowledgements
###end title 53
###begin p 54
###xml 165 173 <span type="species:ncbi:9606">patients</span>
###xml 214 218 <span type="species:ncbi:162683">Mayo</span>
###xml 461 468 <span type="species:ncbi:9606">patient</span>
###xml 647 651 <span type="species:ncbi:162683">Mayo</span>
The authors would like to thank Angelina Lippert for excellent work with the genotyping. We also thank the BARFOT study group for their support and for contributing patients to the study, and all colleagues at the Mayo Clinic, Malmo University Hospital, Lund University Hospital, Spenshult Hospital for Rheumatic Diseases, Karolinska University Hospital, Huddinge, and at the general hospitals in Helsingborg, Kalmar, Kristianstad and Molndal for their help in patient recruitment. This study was supported by NIH grant K24 AR 47578-01A1, the Swedish Rheumatism Association, the Swedish Society for Medicine, Lund University, and a grant from the Mayo Clinic.
###end p 54
###begin article-title 55
The extra-articular features of rheumatoid arthritis. A systematic analysis of 127 cases
###end article-title 55
###begin article-title 56
Extra-articular rheumatoid arthritis: prevalence and mortality
###end article-title 56
###begin article-title 57
###xml 119 127 <span type="species:ncbi:9606">patients</span>
Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis
###end article-title 57
###begin article-title 58
Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years
###end article-title 58
###begin article-title 59
Epidemiology of extra-articular manifestations in rheumatoid arthritis
###end article-title 59
###begin article-title 60
Occurrence of rheumatoid arthritis in a nationwide series of twins
###end article-title 60
###begin article-title 61
Twin concordance rates for rheumatoid arthritis: results from a nationwide study
###end article-title 61
###begin article-title 62
The inheritance of rheumatoid arthritis in Iceland
###end article-title 62
###begin article-title 63
The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis
###end article-title 63
###begin article-title 64
A genomewide screen in multiplex rheumatoid arthritis families suggests genetic overlap with other autoimmune diseases
###end article-title 64
###begin article-title 65
Screening the genome for rheumatoid arthritis susceptibility genes: a replication study and combined analysis of 512 multicase families
###end article-title 65
###begin article-title 66
The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis
###end article-title 66
###begin article-title 67
###xml 18 26 <span type="species:ncbi:9606">patients</span>
Genetic typing of patients with inflammatory arthritis at presentation can be used to predict outcome
###end article-title 67
###begin article-title 68
Correlation between disease phenotype and genetic heterogeneity in rheumatoid arthritis
###end article-title 68
###begin article-title 69
HLA-DRB1 alleles associated with rheumatoid arthritis in Northern Italy: correlation with disease severity
###end article-title 69
###begin article-title 70
Prognostic factors for radiographic damage in early rheumatoid arthritis: a multiparameter prospective study
###end article-title 70
###begin article-title 71
###xml 114 122 <span type="species:ncbi:9606">patients</span>
Impact of shared epitope genotype and ethnicity on erosive disease: a meta-analysis of 3,240 rheumatoid arthritis patients
###end article-title 71
###begin article-title 72
Prognostic markers of radiographic progression in early rheumatoid arthritis
###end article-title 72
###begin article-title 73
HLA antigen associations with extra-articular rheumatoid arthritis
###end article-title 73
###begin article-title 74
Immunogenetic heterogeneity in rheumatoid disease as illustrated by different MHC associations (DQ, Dw and C4) in articular and extra-articular subsets
###end article-title 74
###begin article-title 75
Homozygosity for the HLA-DRB1 allele selects for extraarticular manifestations in rheumatoid arthritis
###end article-title 75
###begin article-title 76
Predictors of extra-articular manifestations in rheumatoid arthritis
###end article-title 76
###begin article-title 77
Role of HLA-DR-DR and DR-DQ associations in the expression of extraarticular manifestations and rheumatoid factor in rheumatoid arthritis
###end article-title 77
###begin article-title 78
###xml 40 48 <span type="species:ncbi:9606">patients</span>
Predominance of HLA-DRB1*0405 in Korean patients with rheumatoid arthritis
###end article-title 78
###begin article-title 79
Association of HLA-DRB1*0405 with extraarticular manifestations and erosions in Singaporean Chinese with rheumatoid arthritis
###end article-title 79
###begin article-title 80
Genetics of rheumatoid arthritis: Is there a pattern predicting extraarticular manifestations?
###end article-title 80
###begin article-title 81
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
###end article-title 81
###begin article-title 82
[The Malmo model for private and public rheumatological outpatient care. Cooperation makes it possible to introduce disease modifying treatment quickly]
###end article-title 82
###begin article-title 83
Remission and response to early treatment of RA assessed by the Disease Activity Score. BARFOT study group. Better Anti-rheumatic Farmacotherapy
###end article-title 83
###begin article-title 84
From genotypes to genes: doubling the sample size
###end article-title 84
###begin article-title 85
Genomic control for association studies
###end article-title 85
###begin article-title 86
Particular HLA-DRB1 shared epitope genotypes are strongly associated with rheumatoid vasculitis
###end article-title 86
###begin article-title 87
###xml 90 97 <span type="species:ncbi:9606">patient</span>
###xml 136 144 <span type="species:ncbi:9606">patients</span>
Lack of association of the HLA-DRB1 shared epitope with rheumatoid nodules: an individual patient data meta-analysis of 3,272 Caucasian patients with rheumatoid arthritis
###end article-title 87
###begin article-title 88
Strong primary selection for the Dw4 subtype of DR4 accounts for the HLA-DQw7 association with Felty's syndrome
###end article-title 88
###begin article-title 89
Major histocompatility complex haplotypic associations in Felty's syndrome and large granular lymphocyte syndrome are secondary to allelic association with HLA-DRB1 *0401
###end article-title 89
###begin article-title 90
Clustering of extra-articular manifestations in rheumatoid arthritis
###end article-title 90
###begin article-title 91
###xml 42 50 <span type="species:ncbi:9606">patients</span>
Rheumatoid vasculitis: experience with 13 patients and review of the literature
###end article-title 91
###begin article-title 92
Functional domains on HLA-DR molecules: implications for the linkage of HLA-DR genes to different autoimmune diseases
###end article-title 92
###begin article-title 93
Perturbation of the T cell repertoire in rheumatoid arthritis
###end article-title 93
###begin article-title 94
Large granular lymphocyte leukemia. Report of 38 cases and review of the literature
###end article-title 94
###begin article-title 95
###xml 24 26 24 26 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
Expansion of unusual CD4+ T cells in severe rheumatoid arthritis
###end article-title 95
###begin article-title 96
Aging, autoimmunity and arthritis: T-cell senescence and contraction of T-cell repertoire diversity: catalysts of autoimmunity and chronic inflammation
###end article-title 96
###begin article-title 97
###xml 13 15 13 15 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
Increased CD4+ T cell infiltrates in rheumatoid arthritis-associated interstitial pneumonitis compared with idiopathic interstitial pneumonitis
###end article-title 97
###begin article-title 98
Factors associated with the development of vasculitis in rheumatoid arthritis: results of a case-control study
###end article-title 98
###begin title 99
Figures and Tables
###end title 99
###begin p 100
###xml 26 40 26 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*0401 </italic>
###xml 68 82 68 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*0401 </italic>
###xml 149 151 149 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 117 125 <span type="species:ncbi:9606">patients</span>
###xml 228 236 <span type="species:ncbi:9606">patients</span>
Variation in frequency of HLA-DRB1*0401 by disease phenotype in RA. HLA-DRB1*0401 was significantly more frequent in patients with Felty's syndrome (P = 0.003) than in non-extra-articular rheumatoid arthritis (RA) controls, but patients with other manifestations did not differ significantly from controls. ExRA, extra-articular RA; ILD, interstitial lung disease; Neuro, vasculitis related neuropathy.
###end p 100
###begin p 101
###xml 50 62 50 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*04 </italic>
###xml 245 257 245 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*04 </italic>
###xml 227 235 <span type="species:ncbi:9606">patients</span>
ExRA manifestations among those carrying carrying HLA-DRB1*04 shared epitope alleles. Shown are odds ratios (ORs) with 95% confidence intervals (CIs) for different extra-articular rheumatoid arthritis (ExRA) manifestations for patients carrying HLA-DRB1*04 shared epitope alleles. ILD, interstitial lung disease.
###end p 101
###begin p 102
Demographic data and clinical predictors of ExRA
###end p 102
###begin p 103
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 92 100 <span type="species:ncbi:9606">patients</span>
aInformation available for 149 extra-articular rheumatoid arthritis (ExRA) and 163 non-ExRA patients.
###end p 103
###begin p 104
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 54 62 <span type="species:ncbi:9606">patients</span>
bInformation available from 120 ExRA and 151 non-ExRA patients. ANA, antinuclear antibody; RA, rheumatoid arthritis; RF, rheumatoid factor; SD, standard deviation.
###end p 104
###begin p 105
###xml 15 24 15 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
###xml 35 43 <span type="species:ncbi:9606">patients</span>
###xml 68 76 <span type="species:ncbi:9606">patients</span>
Frequencies of HLA-DRB1 alleles in patients with ExRA compared with patients with non-extra-articular RA
###end p 105
###begin p 106
###xml 8 10 8 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Global: P = 0.19. ExRA, extra-articular rheumatoid arthritis; SE, shared epitope.
###end p 106
###begin p 107
###xml 31 43 31 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*04 </italic>
The effect of homozygosity for HLA-DRB1*04 shared epitope alleles on risk for severe ExRA manifestations
###end p 107
###begin p 108
CI, confidence interval; ExRA, extra-articular rheumatoid arthritis; OR, odds ratio.
###end p 108
###begin p 109
###xml 15 22 15 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DQ </italic>
###xml 33 41 <span type="species:ncbi:9606">patients</span>
###xml 66 74 <span type="species:ncbi:9606">patients</span>
Frequencies of HLA-DQ alleles in patients with ExRA compared with patients with non-extra-articular RA
###end p 109
###begin p 110
###xml 8 10 8 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Global: P = 0.11. ExRA, extra-articular RA.
###end p 110

